At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 69 enrolled
Drug / intervention
VLY-686 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Proof of Concept, Antipruritic Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating VLY-686 and Placebo for Treatment-resistant Pruritus Associated With Atopic Dermatitis. Completed, enrolled 69 participants across 5 sites.
Detailed Summary
This is randomized, double-blind, placebo-controlled study to test whether VLY-686 can reduce chronic pruritus in subjects with treatment-resistant pruritus associated with atopic dermatitis in comparison with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartDec 2013
Primary CompletionFeb 2015
TodayJul 2026
First PostedDec 6, 2013
Enrollment StartDec 10, 2013
Primary CompletionFeb 19, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 12.6 years ago
Interventions
VLY-686drug
Placebodrug